RxDoctor Payments Data

Kathleen Paz, MD

Family Medicine · The Woodlands, TXNPI 1053623553

Payments from drug & device makers

$6,648in general payments, 2019–2025

Across 353 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$898
  • AstraZeneca$760
  • Lilly USA, LLC$644
  • GSK$542
  • AbbVie$507
  • Johnson & Johnson$300
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,648 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$104,564
Medicare patients
292
Services billed
936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$183,124
MounjaroTirzepatide117$143,734
JardianceEmpagliflozin100$129,366
EliquisApixaban41$56,464
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$31,089
JanuviaSitagliptin Phosphate25$27,456
TrulicityDulaglutide16$23,838
Tresiba Flextouch U-200Insulin Degludec19$21,379
RexultiBrexpiprazole13$21,077
BelsomraSuvorexant17$8,865
DayvigoLemborexant16$5,279
Breo ElliptaFluticasone/Vilanterol11$4,341
Rosuvastatin Calcium277$4,024
Dexlansoprazole DrDexlansoprazole17$3,058
Levothyroxine Sodium318$2,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$898$183,124156 claims
Lilly USA, LLCMounjaro, Trulicity$644$167,572133 claims
Boehringer IngelheimJardiance$115$129,366100 claims
PfizerEliquis$184$56,46441 claims
MerckJanuvia, Belsomra$100$36,32142 claims
GSKTrelegy Ellipta, Breo Ellipta$542$35,42936 claims
Otsuka America Pharmaceutical, Inc.Rexulti$73$21,07713 claims
Eisai Inc.Dayvigo$30$5,27916 claims
AbbVieSynthroid$507$1,64520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →